This year marks the 15th anniversary of the completion of the Human Genome Project. In the decade and a half that has passed since, the genomic revolution has spurred an immeasurable level of excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry. While realizing that promise has turned out to be neither quick nor easy, recent scientific and technological progress has been impressive, pointing to a possible tipping point for mainstream clinical adoption as well as tremendous commercial growth potential for innovators, entrepreneurs, and investors.
For a deep-dive into this current issues to impacting the industry, please join me in South San Francisco on Thursday, December 6, 2018, for the 5th Business of Personalized Medicine Summit. This one day summit explores sustainable business model solutions for entities that are already engaged in the personalized medicine marketplace as well as those seeking to enter the competitive space. Through a series of thought-provoking discussions with key executives from across multiple stakeholder perspectives, the program examines in depth the latest financial, regulatory, policy, R&D, and technology-related complexities, trends, and opportunities impacting the business of personalized medicine, and introduces strategies for successfully navigating the challenging and ever-evolving market.
The day begins with Dr. Helmy Eltoukhy, co-founder and CEO of Guardant Health, a pioneer in the liquid biopsy space that is hot on the heels of an impressive $238M IPO debut – one of the largest in life sciences so far this year. Dr. Eltoukhy will discuss lifecycle strategy and his company's potentially game-changing technology for early cancer detection, Guardant's growth trajectory in a promising yet complex and increasingly competitive field, and what the future holds in terms of innovation and market interest.
Mr. Harry Glorikian will close out this year's program. Mr. Glorikian is an influential leader with more than 20 years of experience in life sciences, healthcare, and health IT who has been a driving force behind major business transformations that accelerated growth, efficiency gains, cost reductions, and competitive advantage for market leaders as well as up-and-coming innovators with next-generation ideas. Drawing from his most recent book, Mr. Harry Glorikian will offer his insights and advice for thriving in the new data-driven market.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.